Request Demo

Last update 05 Jun 2026

Triapine

Last update 05 Jun 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Triapine, 3-AP, NSC#663249

+ [5]

Target

RNRs

Action

inhibitors

Mechanism

RNR inhibitors(Ribonucleotide reductase inhibitors)

Therapeutic Areas

NeoplasmsUrogenital DiseasesOther Diseases+ [2]

Active Indication

Adenosquamous CarcinomaCervical Squamous Cell CarcinomaSquamous Cell Carcinoma+ [9]

Inactive Indication

Acinar Cell CarcinomaAcute Promyelocytic LeukemiaAdenocarcinoma of Esophagus+ [61]

Originator Organization

Nanotherapeutics, Inc.

Active Organization

Nanopharmaceutics, Inc.

National Cancer Institute

Nanotherapeutics, Inc.

Inactive Organization

Vion Pharmaceuticals, Inc.

License Organization

Resilience Government Services, Inc.

Trethera Corp.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC7H9N5S

InChIKeyXMYKNCNAZKMVQN-UHFFFAOYSA-N

CAS Registry143621-35-6

Clinical Trials associated with Triapine

NCT06860594

/ SuspendedPhase 1IIT

A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

Start Date30 Jul 2025

Sponsor / Collaborator

National Cancer Institute

NCT06410248

/ RecruitingPhase 1IIT

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

Start Date23 Jul 2024

Sponsor / Collaborator

Northwestern University

[+2]

NCT05724108

/ Active, not recruitingPhase 2IIT

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.

Start Date30 Aug 2023

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Triapine

100 Translational Medicine associated with Triapine

100 Patents (Medical) associated with Triapine

298

Literatures (Medical) associated with Triapine

01 Jun 2026·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Ribonucleotide reductase regulatory subunit M2 as a macromolecular target bridging small cell lung cancer progression and SARS-CoV-2 infection

Article

Author: Wu, Cong ; Zhang, Xinyi ; Cai, Shanshan ; Yang, Weichang ; Yang, Aoyu ; Xing, Hongquan ; Ye, Xiaoqun

Small cell lung cancer (SCLC) is an aggressive malignancy with profound immunosuppression, yet its vulnerability to COVID-19 and underlying molecular mechanisms remain unclear. We integrated nationwide epidemiological data, transcriptomic profiling, molecular docking, and in vitro validation to investigate this relationship. Analysis of CDC WONDER (1999-2021) revealed a reversal of the long-term decline in the mortality-to-incidence ratio during 2019-2021, while SEER data demonstrated that SCLC patients had the highest COVID-19-specific mortality among lung cancer subtypes, with multivariate Cox regression confirming SCLC as an independent risk factor (HR = 2.99, P < 0.05). Transcriptomic integration identified 64 shared differentially expressed genes enriched in immune-inflammatory and interferon pathways, with RRM2, UBE2C, and CCNB2 consistently upregulated. Experimental validation confirmed markedly elevated RRM2 expression in SCLC cells, and siRNA-mediated knockdown significantly impaired proliferation and migration (P < 0.05). Molecular docking revealed strong binding of RRM2 to SARS-CoV-2 3CLpro (-21.0 kcal/mol), while the RRM2 inhibitor COH29 exhibited superior affinity compared with Triapine and showed robust stability in molecular dynamics simulation. These findings indicate heightened vulnerability of SCLC patients to adverse COVID-19 outcomes and implicate RRM2 as a potential molecular link between aggressive tumor biology and virus-associated host susceptibility.

01 Jun 2026·ChemistryOpen

Evolution of Thiosemicarbazones: From First‐ to Second‐Generation Metal Chelators and Their Reactive Oxygen Species‐Mediated Effects in Melanoma

Review

Author: Parkinson, Christopher J. ; Andrew, Scott D. ; Alim, Rohina

Worldwide, melanoma remains a significant public health concern, with an estimated 325,000 new cases and 57,000 deaths recorded in 2020. If current trends persist, these figures are projected to rise to 510,000 new cases and 96,000 deaths annually by 2040, a 50% and 68% increase, respectively. Despite advances in targeted therapies and immunotherapy, there remains an urgent need for novel, selective treatments—particularly potential low cost oral treatments in low and middle income countries. Thiosemicarbazone (TSC) derivatives, particularly those incorporating ONS (ONS, first generation) and NNS (NNS, second generation) donor motifs, have emerged as promising candidates for melanoma therapy. This review traces the evolution of TSCs from early‐stage compounds to more advanced analogs, emphasizing how structural refinements have enhanced their anticancer potency and selectivity. Classical thiosemicarbazones such as Triapine and Dp44mT display multifaceted mechanisms of action, including potent metal ion chelation, inhibition of ribonucleotide reductase (RR), and the induction of oxidative stress through reactive oxygen species (ROS) generation. The redox activity of their metal complexes facilitates ROS accumulation, which contributes to apoptosis in melanoma cells, that often exhibit elevated basal oxidative stress. Preclinical studies demonstrate strong cytotoxicity and some tumor selectivity for these agents, though clinical translation remains limited. The ongoing development of thiosemicarbazone‐based therapeutics continues to offer promise for more effective and selective melanoma treatment strategies.

01 May 2026·Cancer Reports

Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells

Article

Author: Till Milde ; Natalie Aderhold ; Bernd Gruhn ; Jürgen Sonnemann ; Sabine Becker ; Lisa Immesberger

ABSTRACT:

Background:

Osteosarcoma is the most common bone cancer in children and young adults. Its prognosis has not improved significantly since the introduction of the chemotherapy regimen established about 40 years ago, highlighting the need for new therapeutic strategies.

Aims:

The present study was undertaken to assess the effectiveness of combined inhibition of two promising drug targets, ATR and ribonucleotide reductase (RNR), in osteosarcoma cells.

Methods and Results:

The ATR inhibitor berzosertib and the RNR inhibitors triapine and didox were tested in TP53 wild‐type (U2OS, MG‐63) and mutant (SaOS‐2) osteosarcoma cell lines. Combination effects were examined by flow cytometric analysis of cell death, loss of the mitochondrial membrane potential and DNA fragmentation as well as by caspase 3/7 activity assay and real‐time RT‐PCR. The drug interactions were evaluated using combination index analysis. Single treatment with ATR or RNR inhibitors resulted in mild to moderate effects, whereas combined treatment resulted in strong and synergistic effects. ATR and RNR inhibitors cooperated to elicit loss of the mitochondrial membrane potential, to activate caspase 3/7 and to trigger DNA fragmentation, suggesting that the combination of ATR and RNR inhibitors induced an apoptotic form of cell death. The cytotoxic effects were independent of TP53 mutational status.

Conclusion:

Our study demonstrates that combined inhibition of ATR and RNR was effective in osteosarcoma cells. These in vitro findings offer support for investigating in vivo the potential of a combination of ATR and RNR inhibitors as a new treatment strategy for osteosarcoma.

News (Medical) associated with Triapine

10 Sep 2025

·www.einpresswire.com

Nanopharmaceutics Announces Presentation of National Cancer Institute sponsored Phase I Study with Triapine at ESMO 2025

Phase I Study with Triapine + Lutetium Lu 177 Dotatate in patients with progressive well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) TRON Group Inc. (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, September 10, 2025 / EINPresswire.com / -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced a presentation of the National Cancer Institute (NCI) sponsored Phase I Study 10388 (NCT04234568) “Testing the Addition of an Anti-cancer Drug, Triapine , to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors” in an oral presentation at the European Society for Medical Oncology (ESMO) Congress, held from October 17-21, 2025 in Berlin, Germany. The data will be presented on the October 20th Mini oral session: NETs and endocrine tumours “1709MO - Multi-center NCI-sponsored phase 1 study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)” at the 2025 European Society of Medical Oncology (ESMO) Congress by Aman Chauhan, MD, Associate Professor of Medical Oncology, Leader of Neuroendocrine Tumor Program and Co-Director of Theranostics Program, University of Miami Sylvester Comprehensive Cancer Center. This study was sponsored by the National Cancer Institute (NCI), part of National Institutes of Health, and conducted by the NCI funded Experimental Therapeutics Clinical Trials Network (ECTCN). The end of patient recruitment was recently announced for a NCI-sponsored randomized phase 2 trial 10558 (NCT05724108) “Testing the Effectiveness of an Anti-cancer Drug, Triapine ® , When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors” currently underway at 14 sites across the United States. This 94 patient phase II trial recently passed the pre-planned interim safety review and interim futility assessment and is awaiting primary endpoint maturity. Both studies are being performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics and conducted by ECTCN. About Triapine ® Triapine ® is s synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine ® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Nanopharmaceutics is a subsidiary of TRON Group Inc. (OTC:TGRP). James D Talton Nanopharmaceutics, Inc. +1 386-401-6304 info@nanopharmaceutics.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Phase 1Clinical Result

18 Jul 2025

·www.einpresswire.com

Nanopharmaceutics Announces End of Patient Recruitment for NCI Phase II Study with Triapine for Neuroendocrine Tumors

Nanopharmaceutics Inc. Announces End of Patient Recruitment of NCI Phase II Clinical Study with Lutetium Lu 177 Dotatate +/- Triapine for Neuroendocrine Tumors TRON Group Inc (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, July 18, 2025 / EINPresswire.com / -- ALACHUA, Fla., July 18, 2025 -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 94 patient Phase 2 clinical study “A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors”. The study (NCI protocol 10558, ClinicalTrials.gov Identifier: NCT05724108) is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, conducted by NCI funded Experimental Therapeutics Clinical Trials Network (ETCTN) with the Ohio State University Comprehensive Cancer Center as the lead institution. The randomized phase 2 trial is evaluating (PRIMARY OBJECTIVE) the overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of combination Triapine ® + lutetium Lu 177 dotatate (treatment arm 1) versus standard of care lutetium Lu 177 dotatate alone (treatment arm 2) and (SECONDARY OBJECTIVE) to evaluate progression-free survival (PFS) between the two treatment arms (combination arm 1 versus standard of care arm 2). This phase II trial compares the effect of adding Triapine ® to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine ® may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. This study tests whether adding Triapine ® improves shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone. 94 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. The phase II trial passed the pre-planned interim safety review and interim futility assessment and is awaiting primary endpoint maturity. About Triapine ® Triapine ® is s synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine ® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Nanopharmaceutics is a subsidiary of TRON Group Inc. (OTC:TGRP). James D. Talton, Ph.D. Nanopharmaceutics, Inc. +1 386-401-6304 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Clinical Result

14 May 2024

·www.prnewswire.com

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

ALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma" (ClinicalTrials.gov Identifier: NCT06410248). The primary objective of this phase 1 study will be to determine the recommended phase 2 dose (RP2D) for Triapine® in combination with temozolomide (TMZ). Secondary objectives include evaluation of the safety profile of Triapine® in combination with temozolomide (TMZ), progression-free survival (PFS), overall survival (OS), overall response rate (ORR) per RANO criteria, and quality of life per FACT-Br. The study will recruit 40-45 patients with an established diagnosis of recurrent glioblastoma, and there will be an exploratory arm to investigate drug delivery into brain tumor tissue and target engagement in a cohort who are surgical candidates for re-resection of recurrent glioblastoma. Funding for the study is provided by BrainUp. Oral Triapine® has been shown to be safe, tolerable, and convenient in multiple clinical studies. Ribonucleotide Reductase (RNR) Regulatory Subunit 2 (RRM2) targeting with Triapine® may overcome chemoresistance and improve the clinical efficacy of TMZ therapy. Preliminary research from Dr. Atique Ahmed's lab at Northwestern University has uncovered a critical factor that helps glioblastoma, an aggressive brain cancer, resist chemotherapy treatment. About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is a National Cancer Institute-designated Comprehensive Cancer Center located on Northwestern Memorial Hospital's downtown medical campus in the Streeterville neighborhood of Chicago, Illinois, United States. About BrainUp BrainUp is a nonprofit founded by Dan & Meg Kresach of Frankfort, Illinois. They founded BrainUp after their only child Olivia, was diagnosed 10 years ago with a Glioblastoma at the age of 22 years old. She died on April 19, 2014. The Kresachs formed BrainUp to fund brain cancer research. They have an annual run/walk to raise money for brain cancer research. They have funded over 1.2 million dollars supporting brain cancer research and trials at Chicago healthcare institutions. BrainUp is the financial supporter of Karan Dixit, M.D. (PI) and Atique Ahmed, Ph.D of Northwestern University Chicago, Illinois. To learn more about BrainUp, visit brainup.ngo About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. (OTC: TGRP) James D. Talton, Ph.D. President and Chief Executive Officer 386-401-6304 SOURCE Nanopharmaceutics, Inc.

Phase 1Oligonucleotide

100 Deals associated with Triapine

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11940

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenosquamous Carcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Adenosquamous Carcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016
Cervical Squamous Cell Carcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Cervical Squamous Cell Carcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016
Squamous Cell Carcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Squamous Cell Carcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016
Uterine Cervix Adenocarcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Uterine Cervix Adenocarcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016
Vagina Carcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Vagina Carcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02595879 (ETCTN 9892, Pubmed \| Cancer Chemother Pharmacol)	Phase 1/2	Vaginal Neoplasms \| Locally Advanced Cervical Carcinoma methemoglobin levels \| smoking \| CYP1A2	21	Oral Triapine 100 mg	zreddirtbs(nilayosxae) = almost doubled CYP1A2 mediated triapine clearance trziytdpiy (pgmtdxokvw ) View more	Positive	01 Dec 2025
NCT04234568 (###DELETE, CTgov)	Phase 1	Somatostatin Receptor-Positive Neuroendocrine Tumor \| Gastro-Enteropancreatic Neuroendocrine Tumor	31	Triapine+lutetium Lu 177 dotatate (Escalation Phase)	iloxnedqtj = fqomtngiph gqpxfpmmey (vtknvruzuy, kvuusrmssf - wvtbgemibt)	-	03 Nov 2025
				Triapine+lutetium Lu 177 dotatate (Expansion Phase)	iloxnedqtj = fvlscctwfq gqpxfpmmey (vtknvruzuy, jvujuxmolb - aqvpanckmb)
NCT02595879 (ETCTN 9892, CTgov)	Phase 1	Adenosquamous Carcinoma \| Vagina Carcinoma \| Locally Advanced Cervical Carcinoma ... View more	21	triapine (All Participants)	dlcjcpjiew = gbmftdwcbf nzayxjiguh (tpathtzvzy, wppcdzrljs - hfxxswobut)	-	16 Oct 2024
				Triapine (Triapine (100mg) + Chemoradiation))	ipbgtbazpf = wgxnsdehjz gzkzdczexo (xixnduhmtf, ywoqjaesuk - jdouedqsud) View more
NCT02466971 (NRG-GY006, CTgov)	Phase 3	Adenosquamous Carcinoma \| Vagina Carcinoma \| Cervical Squamous Cell Carcinoma ... View more	450	Intensity-Modulated Radiation Therapy+cisplatin (Arm I (Cisplatin, IMRT or RT, Brachytherapy))	gxqqcupmbg = qpfecqnbgh jsfkuxbnfc (ansvnmlkqn, auegmutmyu - gjobdptkdv) View more	-	05 Jan 2024
				Intensity-Modulated Radiation Therapy+Triapine+cisplatin (Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine))	gxqqcupmbg = nvbzmwroeh jsfkuxbnfc (ansvnmlkqn, eunyhrbflb - mqtacproev) View more
NCT02466971 (NRG-GY006, ASCO2023)	Phase 3	Vaginal Neoplasms \| Locally Advanced Cervical Carcinoma	448	Cisplatin + RT	oyvbttciqm(owgcgrclcp): HR = 1.018 (95% CI, 0.634 - 1.635) View more	Negative	31 May 2023
				Cisplatin + RT + Triapine
NCT04234568 (AACR2023) Manual	Phase 1	Gastro-Enteropancreatic Neuroendocrine Tumor SSTR Expression	31	triapine+Lutetium Dotatate LU-177	xjfivfzmaw(qkliuqkoxy) = One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. uultgtwsfl (zcrdbizkpl ) View more	Positive	14 Apr 2023
NCT04234568 (ASCO_GI2023) Manual	Phase 1	SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor SSTR1 Expression	31	triapine+lutetium Lu-177 dotatate	kohwswpgyy(fuzoystcxg) = olubslpbgc ytexbmpfwm (cojavrqilu ) View more	Positive	24 Jan 2023
NCT04234568 (ASCO2020)	Phase 1	Neuroendocrine Tumors First line	29	Triapine and Lutetium Lu 177 Dotatate	qiwjiygbfl(xokbicuzuc) = teinzwswcl ncxbfdhmof (onwuyqvjnc )	-	25 May 2020
NCT02466971 (Pubmed \| Front Oncol) Manual	Phase 2	Vaginal Neoplasms \| Uterine Cervical Diseases	26	cisplatin+Radiotherapy+triapine	mtkbpfcxkw(cdvtgnltso) = xoojyynftv qurmayqmei (kizoychvnk ) View more	Positive	15 Oct 2019
				cisplatin+Radiotherapy	mtkbpfcxkw(cdvtgnltso) = pqbxnzghjw qurmayqmei (kizoychvnk ) View more
NCT00016874 (Pubmed \| Front Oncol) Manual	Phase 1	Solid tumor	13	cisplatin+paclitaxel+triapine	xbjszhfdrz(hqhicicckb) = triapine (80 mg/m2), cisplatin (50 mg/m2), paclitaxel (80 mg/m2) dzphnxogqh (ogubxlgjvo ) View more	Positive	04 Apr 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis